Renal impairment and Amphotericin B formulations in patients with invasive fungal infections

References

• Kleinberg M. Aspergillosis in the CLEAR outcomes trial: working toward a real-world clinical perspective. Med Mycol 2005; 43: S289–294
   PubMed Web of Science ®Google Scholar
• Brown JM. Fungal infections in bone marrow transplant patients. Curr Opin Infect Dis 2004; 17: 347–352
   PubMed Web of Science ®Google Scholar
• Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34: 909–917
   PubMed Web of Science ®Google Scholar
• Morgan J, Wannemuehler KA, Marr KA, et al. Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program. Med Mycol 2005; 43: S49–58
   PubMed Web of Science ®Google Scholar
• O'Brien, SN, Blijlevens, NM, Mahfouz, TH, Anaissie, EJ. Infections in patients with hematological cancer: recent developments. Hematology. Am Soc Hematol Educ Prog 2003; 438–472.
   Google Scholar
• Singh N, Wagener MM, Marino IR, Gayowski T. Trends in invasive fungal infections in liver transplant recipients: correlation with evolution in transplantation practices. Transplantation 2002; 73: 63–67
   PubMed Web of Science ®Google Scholar
• Upton A, Marr KA. Emergence of opportunistic mould infections in the hematopoietic stem cell transplant patient. Curr Infect Dis Rep 2006; 8: 434–441
   PubMedGoogle Scholar
• Abosaif NY, Tolba YA, Heap M, Russell J, El Nahas AM. The outcome of acute renal failure in the intensive care unit according to RIFLE: model application, sensitivity, and predictability. Am J Kidney Dis 2005; 46: 1038–1048
   PubMed Web of Science ®Google Scholar
• Brivet FG, Kleinknecht DJ, Loirat P, Landais PJ. Acute renal failure in intensive care units–causes, outcome, and prognostic factors of hospital mortality; a prospective, multicenter study. French Study Group on Acute Renal Failure. Crit Care Med 1996; 24: 192–198
   PubMed Web of Science ®Google Scholar
• Levy EM, Viscoli CM, Horwitz RI. The effect of acute renal failure on mortality. A cohort analysis. JAMA 1996; 275: 1489–1494
   PubMed Web of Science ®Google Scholar
• Liano F, Pascual J. Outcomes in acute renal failure. Semin Nephrol 1998; 18: 541–550
   PubMed Web of Science ®Google Scholar
• Chertow GM, Levy EM, Hammermeister KE, Grover F, Daley J. Independent association between acute renal failure and mortality following cardiac surgery. JAMA 1998; 104: 343–348
   PubMed Web of Science ®Google Scholar
• Metnitz PG, Krenn CG, Steltzer H, et al. Effect of acute renal failure requiring renal replacement therapy on outcome in critically ill patients. Crit Care Med 2002; 30: 2051–2058
   PubMed Web of Science ®Google Scholar
• Du Cheyron D, Bouchet B, Parienti JJ, Ramakers M, Charbonneau P. The attributable mortality of acute renal failure in critically ill patients with liver cirrhosis. Intensive Care Med 2005; 31: 1693–1699
   PubMed Web of Science ®Google Scholar
• Sabra R, Branch RA. Amphotericin B nephrotoxicity. Drug Saf 1990; 5: 94–108
   PubMed Web of Science ®Google Scholar
• Rapp RP, Gubbins PO, Evans ME. Amphotericin B lipid complex. Ann Pharmacother 1997; 31: 1174–1186
   PubMedGoogle Scholar
• Mehta J. Do variations in molecular structure affect the clinical efficacy and safety of lipid-based amphotericin B preparations?. Leuk Res 1997; 21: 183–188
   PubMed Web of Science ®Google Scholar
• Hiemenz JW, Walsh TJ. Lipid formulations of amphotericin B. J Liposome Res 1998; 8: 443–467
   Web of Science ®Google Scholar
• Tiphine M, Letscher-Bru V, Herbrecht R. Amphotericin B and its new formulations: pharmacologic characteristics, clinical efficacy, and tolerability. Transpl Infect Dis 1999; 1: 273–283
   PubMedGoogle Scholar
• Dix SP, Andriole VT. Lipid formulations of amphotericin B. Curr Clin Top Infect Dis 2000; 20: 1–23
   PubMedGoogle Scholar
• De Mendonca A, Vincent JL, Suter PM, et al. Acute renal failure in the ICU: risk factors and outcome evaluation by SOFA score. Intensive Care Med 2000; 26: 915–921
   PubMed Web of Science ®Google Scholar
• Consentino F, Chaff C, Piedmonte M. Risk factors influencing survival in ICU acute renal failure. Nephrol Dial Transplant 1994; 9: 179–182
   Google Scholar
• Uchino S, Kellum JA, Bellomo R, et al. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA 2005; 294: 813–818
   PubMed Web of Science ®Google Scholar
• Ympa YP, Sakr Y, Reinhart K, Vincent JL. Has mortality from acute renal failure decreased? A systematic review of the literature. Am J Med 2005; 118: 827–832
   PubMed Web of Science ®Google Scholar
• Wyatt CM, Arons RR. The burden of acute renal failure in nonrenal solid organ transplantation. Transplantation 2004; 78: 1351–1355
   Google Scholar
• Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003; 349: 931–940
   PubMed Web of Science ®Google Scholar
• Miralbell R, Sancho G, Bieri S, et al. Renal insufficiency in patients with hematologic malignancies undergoing total body irradiation and bone marrow transplantation: a prospective assessment. Int J Radiat Oncol Biol Phys 2004; 58: 809–816
   PubMed Web of Science ®Google Scholar
• Gruss E, Bernis C, Tomas JF, et al. Acute renal failure in patients following bone marrow transplantation: prevalence, risk factors and outcome. Am J Nephrol 1995; 15: 473–479
   PubMed Web of Science ®Google Scholar
• Letourneau I, Dorval M, Belanger R, et al. Acute renal failure in bone marrow transplant patients admitted to the intensive care unit. Nephron 2002; 90: 408–412
   PubMed Web of Science ®Google Scholar
• Kist-van Holthe JE, Goedvolk CA, Brand R, et al. Prospective study of renal insufficiency after bone marrow transplantation. Pediatr Nephrol 2002; 17: 1032–1037
   Web of Science ®Google Scholar
• Van Why SK, Friedman AL, Wei LJ, Hong R. Renal insufficiency after bone marrow transplantation in children. Bone Marrow Transplant 1991; 7: 383–388
   PubMed Web of Science ®Google Scholar
• Ankersmit HJ, Deicher R, Moser B, et al. Impaired T cell proliferation, increased soluble death-inducing receptors and activation-induced T cell death in patients undergoing haemodialysis. Clin Exp Immunol 2001; 125: 142–148
   PubMedGoogle Scholar
• Fortun JP, Martin-Davila S, Moreno E, et al. Risk factors for invasive aspergillosis in liver transplant recipients. Liver Transplant 2002; 8: 1065–1070
   PubMed Web of Science ®Google Scholar
• Singh N, Paterson DL. Aspergillus infections in transplant recipients. Clin Microbiol Rev 2005; 18: 44–69
   PubMed Web of Science ®Google Scholar
• Paphitou NI, Ostrosky-Zeichner L, Rex JH. Rules for identifying patients at increased risk for candidal infections in the surgical intensive care unit: approach to developing practical criteria for systematic use in antifungal prophylaxis trials. Med Mycol 2005; 43: 235–243
   PubMed Web of Science ®Google Scholar
• Stevens LA, Levey AS. Measurement of kidney function. Med Clin North Am 2005; 89: 457–473
   PubMed Web of Science ®Google Scholar
• Erley CM, Bader BD, Berger ED, et al. Plasma clearance of iodine contrast media as a measure of glomerular filtration rate in critically ill patients. Crit Care Med 2001; 29: 1544–1550
   Google Scholar
• Wright JG, Boddy AV, Highley M, et al. Estimation of glomerular filtration rate in cancer patients. Br J Cancer 2001; 84: 452–459
   PubMed Web of Science ®Google Scholar
• Herget-Rosenthal S, Marggraf G, Husing J, et al. Early detection of acute renal failure by serum cystatin C. Kidney Int 2004; 66: 1115–1122
   PubMed Web of Science ®Google Scholar
• Mendelssohn DC, Barrett BJ, Brownscombe LM, et al. Elevated levels of serum creatinine: recommendations for management and referral. CMAJ 1999; 161: 413–417
   Web of Science ®Google Scholar
• Gault MH, Longerich LL, Harnett JD, Wesolowski C. Predicting glomerular function from adjusted serum creatinine. Nephron 1992; 62: 249–256
   PubMed Web of Science ®Google Scholar
• Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461–470
   PubMed Web of Science ®Google Scholar
• Poggio ED, Nef PC, Wang X, et al. Performance of the Cockcroft-Gault and modification of diet in renal disease equations in estimating GFR in ill hospitalized patients. Am J Kidney Dis 2005; 46: 242–252
   PubMedGoogle Scholar
• Poggio ED, Wang X, Weinstein DM, et al. Assessing glomerular filtration rate by estimation equations in kidney transplant recipients. Am J Transplant 2006; 6: 100–108
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Hiemenz JW, Seibel NL, et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998; 26: 1383–1396
   PubMed Web of Science ®Google Scholar
• Subira M, Martino R, Gomez L, Marti JM, Estany C, Sierra J. Low-dose amphotericin B lipid complex versus conventional amphotericin B for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies-a randomized, controlled trial. Eur J Haematol 2004; 72: 342–347
   PubMed Web of Science ®Google Scholar
• Bates DW, Su L, Yu DT, et al. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis 2001; 32: 686–693
   PubMed Web of Science ®Google Scholar
• Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P. Acute renal failure-definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004; 8: R204–212
   PubMed Web of Science ®Google Scholar
• Esson ML, Schrier RW. Diagnosis and treatment of acute tubular necrosis. Ann Intern Med 2002; 137: 744–752
   PubMed Web of Science ®Google Scholar
• Kaloyanides GJ. Antibiotic-related nephrotoxicity. Nephrol Dial Transplant 1994; 9: 130–134
   PubMed Web of Science ®Google Scholar
• Gubbins PO, Penzak SR, Polston S, McConnell SA, Anaissie E. Characterizing and predicting amphotericin B-associated nephrotoxicity in bone marrow or peripheral blood stem cell transplant recipients. Pharmacotherapy 2002; 22: 961–971
   PubMed Web of Science ®Google Scholar
• Alexander BD, Wingard JR. Study of renal safety in amphotericin B lipid complex-treated patients. Clin Infect Dis 2005; 40: S414–421
   PubMed Web of Science ®Google Scholar
• Sabra R, Takahashi K, Branch RA, Badr KF. Mechanisms of amphotericin B-induced reduction of the glomerular filtration rate: a micropuncture study. J Pharmacol Exp Ther 1990; 253: 34–37
   PubMed Web of Science ®Google Scholar
• Walker RJ, Duggin GG. Drug nephrotoxicity. Annu Rev Pharmacol Toxicol 1988; 28: 331–345
   PubMed Web of Science ®Google Scholar
• Ng AW, Wasan KM, Lopez-Berestein G. Development of liposomal polyene antibiotics: an historical perspective. J Pharm Pharm Sci 2003; 6: 67–83
   PubMed Web of Science ®Google Scholar
• Fanos V, Cataldi L. Amphotericin B-induced nephrotoxicity: a review. J Chemother 2000; 12: 463–470
   PubMed Web of Science ®Google Scholar
• Gallis HA, Drew RH, Pickard WW. Amphotericin B: 30 years of clinical experience. Rev Infect Dis 1990; 12: 308–329
   PubMedGoogle Scholar
• Boswell GW, Bekersky I, Buell D, Hiles R, Walsh TJ. Toxicological profile and pharmacokinetics of a unilamellar liposomal vesicle formulation of amphotericin B in rats. Antimicrob Agents Chemother 1998; 42: 263–268
   PubMed Web of Science ®Google Scholar
• Wong-Beringer A, Jacobs RA, Guglielmo BJ. Lipid formulations of amphotericin B: clinical efficacy and toxicities. Clin Infect Dis 1998; 27: 603–618
   PubMed Web of Science ®Google Scholar
• Williams P, Waskin H, Bolcsak L, Swenson C. Amphotericin B concentrations in autopsy tissues of organ transplant patients administered amphotericin B lipid complex injection. Transplantation 1999; 67: S93
   Google Scholar
• Barrett JP, Vardulaki KA, Conlon C, et al. A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations. Clin Ther 2003; 25: 1295–1320
   PubMed Web of Science ®Google Scholar
• Anaissie, EJ, White, M, Uzun, O, , et al. Amphotericin B lipid complex versus amphotericin B for treatment of invasive candidiasis: a prospective, randomized, multicenter trial [abstract LM21]. In:. Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. The American Society of Microbiology (ASM), San Francisco, CA, 1995; 330.
   Google Scholar
• Luke RG, Boyle JA. Renal effects of amphotericin B lipid complex. Am J Kidney Dis 1998; 31: 780–785
   PubMed Web of Science ®Google Scholar
• Sharkey PK, Graybill JR, Johnson ES, et al. Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1996; 22: 315–321
   PubMed Web of Science ®Google Scholar
• Miller CB, Waller EK, Klingemann HG, et al. Lipid formulations of amphotericin B preserve and stabilize renal function in HSCT recipients. Bone Marrow Transplant 2004; 33: 543–548
   PubMed Web of Science ®Google Scholar
• Macaulay SS, Martin JE, Zarnke KB. Amphotericin B for the treatment of systemic fungal infections: meta-analysis of conventional versus lipid formulations [abstract M–888]. Program and Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, (San Diego, CA). Washington, DC 2002; 393
   Google Scholar
• Martino R. Efficacy, safety and cost-effectiveness of Amphotericin B Lipid Complex (ABLC): a review of the literature. Curr Med Res Opin 2004; 20: 485–504
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999; 340: 764–771
   PubMed Web of Science ®Google Scholar
• Prentice HG, Hann IM, Herbrecht R, et al. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol 1997; 98: 711–718
   PubMed Web of Science ®Google Scholar
• Leenders AC, Daenen S, Jansen RL, et al. Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections. Br J Haematol 1998; 103: 205–212
   PubMed Web of Science ®Google Scholar
• Cagnoni PJ. Liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients. J Antimicrob Chemother 2002; 49: 81–86
   Google Scholar
• White MH, Anaissie EJ, Kusne S, et al. Amphotericin B colloidal dispersion vs. amphotericin B as therapy for invasive aspergillosis. Clin Infect Dis 1997; 24: 635–642
   PubMed Web of Science ®Google Scholar
• White MH, Bowden RA, Sandler ES, et al. Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia. Clin Infect Dis 1998; 27: 296–302
   PubMed Web of Science ®Google Scholar
• Bowden R, Chandrasekar P, White MH, et al. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis 2002; 35: 359–366
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Pappas P, Winston DJ, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002; 346: 225–234
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Teppler H, Donowitz GR, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004; 351: 1391–1402
   PubMed Web of Science ®Google Scholar
• Cornely OA, Maertens JA, Bresnik M, et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 2007; 44: 1289–1297
   PubMed Web of Science ®Google Scholar
• Wingard JR, White MH, Anaissie E, et al. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group. Clin Infect Dis 2000; 31: 1155–1163
   PubMed Web of Science ®Google Scholar
• Frothingham R. Mortality rates in comparative trials of formulations of amphotericin B. Clin Infect Dis 2001; 33: 582–583
   Google Scholar
• Wingard JR. Lipid formulations of amphotericins: are you a lumper or a splitter?. Clin Infect Dis 2002; 35: 891–895
   PubMed Web of Science ®Google Scholar
• Imhof A, Walter RB, Schaffner A. Continuous infusion of escalating doses of amphotericin B deoxycholate: an open label observational study. Clin Infect Dis 2003; 36: 943–951
   PubMed Web of Science ®Google Scholar
• Pappas PG. Amphotericin B lipid complex in the treatment of invasive fungal infections: results of the Collaborative Exchange of Antifungal Research (CLEAR), an industry-supported patient registry. Clin Infect Dis 2005; 40: S379–383
   PubMed Web of Science ®Google Scholar
• Chandrasekar PH, Ito JI. Amphotericin B lipid complex in the management of invasive aspergillosis in immunocompromised patients. Clin Infect Dis 2005; 40: S392–400
   PubMedGoogle Scholar
• Ito JI, Hooshmand-Rad R. Treatment of Candida infections with amphotericin B lipid complex. Clin Infect Dis 2005; 40: S384–391
   Google Scholar
• Baddour LM, Perfect JR, Ostrosky-Zeichner L. Successful use of amphotericin B lipid complex in the treatment of cryptococcosis. Clin Infect Dis 2005; 40: S409–413
   PubMed Web of Science ®Google Scholar
• Saliba F, Cheron N, Ichaï P, et al. A prospective French national survey to assess renal safety of amphotericin B lipid complex and liposomal amphotericin B. Int J Infect Dis 2006; 10: S68
   Google Scholar
• Fleming RV, Kantarjian HM, Husni R, et al. Comparison of amphotericin B lipid complex (ABLC) vs. ambisome in the treatment of suspected or documented fungal infections in patients with leukemia. Leuk Lymphoma 2001; 40: 511–520
   PubMed Web of Science ®Google Scholar
• Lopez Sastre JB, Coto Cotallo GD, Fernandez CB. Neonatal invasive candidiasis: a prospective multicenter study of 118 cases. Am J Perinatol 2003; 20: 153–163
   PubMed Web of Science ®Google Scholar
• Clark AD, McKendrick S, Tansey PJ, Franklin IM, Chopra R. A comparative analysis of lipid-complexed and liposomal amphotericin B preparations in haematological oncology. Br J Haematol 1998; 103: 198–204
   PubMed Web of Science ®Google Scholar
• McKechnie, M, Rotstein, C, McTaggart, B. A multi-center, retrospective comparison of the nephrotoxic effects of amphotericin B lipid complex and liposomal amphotericin B. In:. Program and Abstracts of the 13th Focus on Fungal Infections Meeting, (Maui, Hawaii). Chicago, IL: The Infectious Disease Society of America; 2003: A48.
   Google Scholar
• McTaggart, B, McKechnie, M, Gin, A, Bombassaro, A, Lui, E, Carle, S. Comparative nephrotoxic effects of amphotericin B lipid complex and liposomal amphotericin B in patients with hematological malignancy [abstract M–965]. In:. Program and Abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. The American Society of Microbiology (ASM), San Francisco, CA; 2003: 447.
   Google Scholar
• Couch, K, Chan, S, Cincotta, E, Piper, JP, Forrest, G. Comparative nephrotoxicity, adverse events, and clinical outcomes of lipid-associated amphotericin B products. In: Program and Abstracts of the 13th Focus on Fungal Infections Meeting, (Maui, Hawaii). Chicago, IL: The Infectious Diseases Society of America; 2003: A47.
   Google Scholar
• Cannon JP, Garey KW, Danziger LH. A prospective and retrospective analysis of the nephrotoxicity and efficacy of lipid-based amphotericin B formulations. Pharmacotherapy 2001; 21: 1107–1114
   PubMed Web of Science ®Google Scholar